Amphion Innovations plc
IP Developments and New Chairman

London and New York, 30 March 2011– Amphion Innovations plc (LSE: AMP) (“Amphion” or the “Company”), the developer of medical and technology businesses, today announces that its wholly owned subsidiary, DataTern, Inc., has agreed further licenses involving its U.S. Patents 6,101,502 and 5,937,402, generating total revenues of $665,000.

Since inception in 2008, DataTern has generated total revenues of approximately $17 million by signing licenses with companies from the financial, credit card, retail, leisure, healthcare, airline, e-commerce, oil and gas, insurance, and software industries.

Richard Morgan, CEO of Amphion, commented:

DataTern continues to make progress. We continue to have confidence in the quality of the patents owned by DataTern and we are very active in seeking additional licensees to this important technology. In parallel we continue to look for ways to improve the economics of the programme in order to maximize cash flow and ensure a good return on investment over the next few years.

The Company is also pleased to announce that as of 1 May 2011, R. James Macaleer will take over as Chairman of the Board of Amphion. Mr. Macaleer has been a Non-executive Director since 2005.

For further information please contact

Amphion Innovations plc
Charlie Morgan
+1 212 210 6224

Cardew Group
Tim Robertson/ Jamie Milton
+44 20 7930 0777

Seymour Pierce
Freddy Crossley/ Mark Percy
+44 20 7107 8000

About Amphion Innovations plc
Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number that grows rapidly each year.

On the web: